News Posts List
Study examines different types of surgery for kidney cancer
08/02/2016
For completely endophytic kidney tumors, which grow inward, both open partial nephrectomy (OPN) and robotic partial nephrectomy (RPN) led to excellent patient outcomes in a recent study.
Precision Therapy Offers Promise for Renal Cell Carcinoma
08/02/2016
Gurkamal Chatta, MD, professor of oncology and chief of genitourinary oncology at Roswell Park Cancer Institute in Buffalo, New York, said that improved understanding of kidney cancer is long overdue.
Top-Line Results From Phase 3 S-TRAC Trial
07/17/2016
S-TRAC is the First RCC Trial of a Tyrosine Kinase Inhibitor to Prolong Disease-Free Survival in the Adjuvant Setting
FREE Kidney Cancer Awareness Ribbon!
06/30/2016
Send for your FREE orange awareness ribbon and share the image, too!
Finding a niche for girentuximab in metastatic renal cell carcinoma
06/29/2016
A small phase II study highlights modest efficacy and a concerning safety profile associated with this compound in patients with metastatic RCC.
What to ask your doctor about #KidneyCancer
06/16/2016
Knowing what questions to ask is critically important to your care,
CCF/KCA Young Investigator Awards
05/31/2016
Young Investigator Awards (YIA) sponsored by the Conquer Cancer Foundation and the Kidney Cancer Association
AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study
05/28/2016
The Phase 3 trial is expected to enroll approximately 322 patients with recurrent or metastatic RCC who have failed at least two prior regimens, including VEGFR-TKI therapy (other than sorafenib).
FDA Approves Lenvatinib) for Treatment of mRCC
05/16/2016
U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma...
First Patient Dosed In Phase 1/2 Trial Evaluating CRLX101 In Combination With LYNPARZA
05/11/2016
The U.S. FDA has granted CRLX101 Orphan Drug designation for the treatment of ovarian cancer and Fast Track designation in combination with AvastinĀ® in metastatic renal cell carcinoma.